Finding Markers That May Predict Cancer Risk in Adults
Compares samples and lifestyle data from cancer patients and healthy adults to find risk markers.
Plain-language title generated from the registry record
Registry title: Predicting Cancer Risk With Digital and Molecular Markers
Key facts
- Where
- Please Refer to Project Homepage For Details (see Link Below), GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women, some with breast, lung, colorectal or gynecologic cancer and some without cancer, to find markers that predict cancer risk.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- People with cancer need a current or past diagnosis of breast, lung, colorectal or gynecologic cancer (ovarian, endometrial, cervical, fallopian tube, vaginal or vulvar). Women without cancer can also join.
Main reasons for not taking part
- Known infection with HIV, hepatitis A, B or C
- Active SARS-CoV2 infection
- Acute severe or potentially life-threatening illness (except the cancers named for the cancer group)
- No smartphone that can run the BayPass app
- No written informed consent
Read by machine on 12 November 2026.
Where in Germany
- DigiOnko PräventionsmobilPlease Refer to Project Homepage For Details (see Link Below), GermanyContact: Hanna Hübner, PD Dr. rer. nat. med. habil.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Erlangen-Nürnberg Medical School
- Trial code
- NCT06962670
- Record updated
- 8 May 2025
- Original description
The goal of this study is to identify new markers to predict the risk of developing cancer, primarily breast cancer. For this purpose, researchers will compare data obtained from cancer patients and healthy individuals. If characteristic differences are identified, e.g. in biomarkers, life style or family history, this may indicate a person's increased risk of developing cancer.Read full original descriptionShow less
Digital and Molecular Detection of Markers for Disease Risk Prediction, Improvement of Diagnostic Detection Accuracy and Implementation for Preventive Measures of Cancer - A Combined Case-control and Cohort Study
The goal of this study is to identify new markers to predict the risk of developing cancer, primarily breast cancer. For this purpose, researchers will compare data obtained from cancer patients and healthy individuals. If characteristic differences are identified, e.g. in biomarkers, life style or family history, this may indicate a person's increased risk of developing cancer.
Inclusion: Biological adult (at least 18 years old) women; Written informed consent for study participation and processing of personal data; Own smartphone that can run the BayPass mobile application and willingness to use said smartphone for study purposes; Additional inclusion criterion for case group:; Pre-existing or current diagnosis of at least one of the following oncological diseases: breast cancer, lung cancer, colorectal cancer, gynecologic cancer (incl. ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, vaginal cancer and vulvar cancer).
Exclusion: Known infection with HIV (Human Immunodeficiency Virus), HepA (Hepatitis A), HepB (Hepatitis B), HepC (Hepatitis C) or active SARS-CoV2 (Severe acute respiratory syndrome coronavirus type 2) infection; Acute severe or potentially life-threatening illness, except those specified in inclusion criterion #4.